GlassScriptPhysician profile
Aruge Lutaf
NPI 1144727140
$3,366.49
in general payments reported to CMS, 2019-2025
20 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,045 · 2024: $1,076 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.50 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $647.89 | 2023-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $589.40 | 2023-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $324.00 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cook Medical LLC | $275.64 | 2024 | Zilver Ptx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.75 | 2023-2025 | Lifevest |
| Abiomed | $228.21 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $190.21 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $178.33 | 2024-2025 | Amvuttra |
| Amgen INC. | $149.51 | 2023-2024 | Repatha |
| United Therapeutics Corporation | $124.39 | 2025 | Tyvaso |
| Pfizer INC. | $105.46 | 2023-2025 | |
| Abbott Laboratories | $85.56 | 2024-2025 | Agilis Hispro, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Irhythm Technologies, INC. | $77.05 | 2023 | Zio Xt Patch |
| Bridgebio Pharma, INC. | $31.44 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $23.47 | 2024 | Assure Wcd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $22.93 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $22.83 | 2023 | Verquvo |
| W. L. Gore & Associates, INC. | $15.63 | 2024 | Gore Cardioform Septal Occluder |
| Boston Scientific Corporation | $14.92 | 2023 | |
| Medtronic, INC. | $14.87 | 2025 | Linq II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruge Lutaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.